
Insights for eye care providers.

This medical device is the first retinal eye-movement monitor for non-invasive, objective clinical assessments.

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

It is important that clinicians are prepared with alternative methods for patients experiencing refractory CME after failed improvement with the agents that are most frequently used.

Catch up on what happened in optometry during the week of May 8-May 12.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego where he shared insights from his presentation comparing patient results of the Hydrus stent and the iStent inject W with or without ABiC (or ab-interno canaloplasty).

Ocular trauma is a leading cause of monocular blindness in the US and is the second most common reason for eye-related hospitalizations

Lance Kugler, MD, recapped his presentation and findings on the safety of office space cataract surgery with the Ophthalmology Times© team at the ASCRS annual meeting in San Diego.

Acceptance is based on two phase 3 studies that demonstrated early and sustained vision improvement, meeting primary endpoint of non-inferiority compared to aflibercept.

Diagnostic test results may vary in the same patient on the same day.

Edward Hu, MD, PhD, discussed his paper on the single surgeon retrospective comparative analysis of 517 eyes of two subgroups of routine cataract surgery at the 2023 ASCRS annual meeting in San Diego.

Although the use of atropine is not necessarily novel in the myopia management world, the fact that practitioners may soon have an FDA approved formulation of atropine is new and exciting.

Zeba Syed, MD, from Wills Eye Hospital discussed their research on corneal swelling and dynamics during corneal collagen crosslinking at the 2023 ASCRS annual meeting in San Diego.

The evolution opens doors for the treatment of neurotrophic keratitis and beyond.

Mydcombi is the first FDA-approved, fixed-combination of tropicamide and phenylephrine for the reversal of mydriasis.

The iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has a PDUFA date of December 22, 2023.

A holistic approach provides better eye care for patients.

In this recent study, Bharti Nihalani-Gangwani, MD, and Deborah VanderVeen, MD, reported that 29% developed glaucoma in a large infant cohort and the risk factors at the American Society of Cataract and Refractive Surgery annual meeting in San Diego.

Lucie Moore, BSc, in a presentation at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, said the study focused on identifying factors that could put patients at a higher risk for developing dry eye disease.

Umida F. Mavlyanova, PhD, in a presentation at the American Society for Cataract and Refractive Surgery’s annual meeting in San Diego, detailed how patients diagnosed with end-stage chronic renal failure displayed deceased blood flow in the orbital artery, the central artery of the retina and the posterior short ciliary arteries.

William Trattler, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on progressive keratoconus in older patients with delayed corneal cross-linking treatment at the ASCRS annual meeting in San Diego.

Speaking at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Marcony Santhiago, MD, points out there are subtle differences in patients with keratoconus that was progressing compared with patients whose disease was stable and healthy control subjects.

Catch up on what happened in optometry during the week of May 1-May 5.

Xiongfei Liu, MD, is presenting a talk entitled, "Effectiveness and safety of combining 2 MIGS devices in patients with open angle glaucoma," at ASCRS 2023 in San Diego, California.

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Erisa Yotsukura, MD, PhD, offered details of a study examining an IOL that transmits violet light and a second option that does not, and they believe this can affect differences in the choroidal thickness after cataract surgery.

Preeya Gupta, MD, reported results of the trials at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, showed that CSF-1, a low dose pilocarpine with an optimized formulation, demonstrated significant 2-line improvement from baseline.

Jason Bacharach, MD, presented results at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, highlighting that a large phase 3 clinical trial demonstrated no relevant differences between the 2 formulations.

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

Inder Paul Singh, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on intraoperative OCT during glaucoma at the ASCRS annual meeting in San Diego.

Alvin Liu, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on deep learning and 3D OCT at the ASCRS annual meeting in San Diego.